CarnaBioC1763102:Oral AS-1763 in Previous Treated Lymphoma or Non-Hodgkin Lymphoma - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.
Previously Treated Lymphoma or Non-Hodgkin Lymphoma
Who Can Participate in the Study?
Adults and children younger than 65 who:
- Are diagnosed with lymphoma or non-Hodgkin lymphoma
- Have at least 1 radiographically measurable lesion
- Have been treated with at least 2 previous lines of therapy that were not effective
For more information, contact the study team at tenesia.carey@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (by chance) to take a certain dose of the study drug. The dose levels you might get are:
- 300 mg; OR
- 400 mg; OR
- 500 mg
Depending on your treatment history and when you join the study, you might receive any of these 3 dose levels or you might receive either the 400 mg or 500 mg dose. The study team will let you know what dose levels are possibilities for you before you choose to join the study.
This study will last for approximately 22 months and involve about 29 visits to our clinic.
Study Details
